Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SINPAIN

Financiado

A game changer for the treatment of osteoarthritis: a cost effective combined ad...

A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis According to the WHO Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden disease, which makes it a research priority in Europe. There is no cure for OA and SoA treatme... ver más

31/10/2026

CIDETEC

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

FUNDACION CIDETEC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 14M€

Fecha límite participación Sin fecha límite de participación.

Ver 13 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-19

HORIZON-HLTH-2021-TOOL-06-02: Next generation advanced therapies... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

13 Participantes

CIDETEC

1.29M€ | Lider

I3S INSTITUTO DE INVESTIGAC...

515.52K€ | Participante

INSERM

309.15K€ | Participante

AO-FORSCHUNGSINSTITUT DAVOS

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CPP2021-008792 Desarrollo de una terapia de primera clase para el tratamien... 542K€ Cerrado

TargetCaRe Targeting Cartilage Regeneration in joint and intervertebral... 4M€ Cerrado

DesiRTA Localize and Controlled co-delivery of AuNPs conjugated siRN... 200K€ Cerrado

PROTO PROTO - Advanced PeRsOnalized Therapies for Osteoarthritis –... 7M€ Cerrado

PGC2018-102047-B-I00 ANDAMIOS BIOHIBRIDOS ASOCIADOS CON APATITOS NANOCRISTALINOS... 133K€ Cerrado

RTI2018-094734-B-C21 UTILIDAD TERAPEUTICA Y DE NUEVOS TRATAMIENTOS PARA LAS ENFER... 230K€ Cerrado

Duración del proyecto: 53 meses Fecha Inicio: 2022-05-19
Fecha Fin: 2026-10-31

Líder del proyecto

FUNDACION CIDETEC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 2-3 | 14M€

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto According to the WHO Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden disease, which makes it a research priority in Europe. There is no cure for OA and SoA treatments need to be reconsidered. Current pharmacological interventions consist of analgesic, anti-inflammatory drugs as well as intraarticular steroids and hyaluronic acid (IA-HA) with moderate efficacy and associated long-term side effects. New medications are thus needed both to alleviate pain and slow down disease progression. Taking advantage of the explosion of RNA technologies in the last years, SINPAIN aims to develop a pipeline of siRNA-based therapy built on the combination of current technologies (dyanmic IA-HA and nanocarriers) that will be designed step-by-step in order to reach a successful management of inflammation and innervation therapy for the treatment of early (grade 0-1) and later stages (grade 3-4) of knee osteoarthritis (OA). To do so, a nanoformulation composed of functional IA-HA that can be loaded with vectors, for the delivery of siRNA targeting IL1? and NGF, and nanocarriers will be developed. In parallel, large effort will focus on understanding the pathological mechanisms of OA. To validate efficacy in relevant potency assays, 3D coculture models will be developed with human cells and tested in unique bioreactors mimicking joint environment and biomechanics. With the identified cell targets, IA-HA will be modified with immunomodulator peptide which will activate the adaptive immune response, responsible for OA regeneration. The 4 pipeline products of SINPAIN will be validated in vivo in a relevant OA model with SoA techniques that will demonstrate the reduced inflammation and pain, as well as the cartilage regeneration for the last product. Taking advantage of all the data obtained during the project, a decision-making tool based on machine learning will be validated to offer patients a personalized therapy.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores